ArticleJournal of leukocyte biology2025
Lyn expression in macrophages promotes TLR activation and restricts proliferation in an isoform-independent manner.
Article in Journal of leukocyte biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cumulative expression of the two Lyn isoforms creates a threshold for macrophage signaling in the absence of receptor engagement.Journal of leukocyte biology · 2026Article
- Basal phosphorylation of SHIP1 by Lyn suppresses proinflammatory signaling in the absence of a phagocytic synapse.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
Toll-like receptor (TLR) signaling is vital for antimicrobial macrophage function, and its dysregulation is associated with diseases such as lupus, multiple sclerosis, pulmonary fibrosis, and cancer. The Src-family kinase Lyn may have net activating or inhibitory effects on TLR signaling, yet distinct functions of the Lyn splice variants LynA and LynB in TLR signaling have not been investigated. We used isoform-specific Lyn knockout mice (LynAKO and LynBKO) to interrogate the contribution of each isoform to TLR signaling in bone-marrow-derived macrophages. Bulk RNA sequencing and cytokine analyses revealed that complete Lyn deficiency (LynKO) dampened TLR4- and TLR7-induced inflammatory gene expression and production of tumor necrosis factor but enhanced the expression of genes responsible for synthesizing the extracellular matrix and promoting proliferation. Despite reduced expression of total Lyn in single-isoform-knockout bone-marrow-derived macrophages, expression of either LynA or LynB alone was sufficient to preserve a wild-type-like transcriptome at steady state and after treatment with the TLR7 agonist R848. However, LynAKO and LynBKO macrophages did have impaired production of tumor necrosis factor in response to the TLR4 agonist lipopolysaccharide. Additionally, LynAKO and LynBKO macrophages were as hyperproliferative as LynKO cells. These data suggest that Lyn promotes macrophage activation in response to TLR signaling and restrains aberrant proliferation and matrix deposition in a dose-dependent rather than isoform-specific manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.